What's going on in today's after hours session After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.
FEMY Stock Earnings: Femasys Misses EPS, Misses Revenue for Q2 2024 FEMY stock results show that Femasys missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market.
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024 FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023 FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of awareness. ARPA-H Sprint for Women's Health aims to promote innovative solutions.
